Cardiovascular polypills from Cipla, Dr Reddy's to enter trial in UK and India
This article was originally published in Scrip
Executive Summary
Cipla hopes to start Indian trials this year with its "primary" version of the "polypill", which comprises three antihypertensives at half the standard dose and a statin, and is aimed at preventing heart attacks and strokes. Another Indian company, Dr Reddy's Laboratories, also appears to have made progress in developing its polypill, for those with cardiovascular disease, with trials ongoing globally.